Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line | ||||
Research in Oncology | ||||
Article 1, Volume 17, Issue 2, December 2021, Page 42-50 PDF (518.25 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/resoncol.2021.70125.1134 | ||||
View on SCiNiTO | ||||
Authors | ||||
Aida A. Guemei 1; Eman Dessouky2; Thanaa I. Shalaby3; Sarah K. Amer4; Rasha Nassra2 | ||||
1Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt | ||||
2Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt | ||||
3Medical Biophysics Department, Medical Research Institute, Alexandria University, Alexandria, Egypt | ||||
4Department of Pharmaceutics, Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt | ||||
Abstract | ||||
Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold nanoparticles (GNPs) conjugated with cisplatin and /or gemcitabine for the treatment of NSCLC. Methods: MTT cytotoxicity assay was carried out in NSCLC cell line (A549). Cell viabilities were determined after treatment with different concentrations of cisplatin, gemcitabine, GNPs-cisplatin or GNPs-gemcitabine. Combinations of variable ratios (1:1, 1:2, 2:1, 1:9, 9:1) of cisplatin + gemcitabine, GNPs-cisplatin + gemcitabine, cisplatin + GNPs-gemcitabine or GNPs-cisplatin + GNPs-gemcitabine were also tested. The Combination Index was computed for each combination concentration ratio and dose to know the best synergistic effect. Histological changes and multidrug resistance were studied. Results: The 1:1 ratio combination concentration showed the highest synergistic effect among all concentration ratios (p < 0.001). Multidrug resistance revealed that the percent efflux of the GNPs-cisplatin + GNPs-gemcitabine combination with a 1:1 ratio was the minimal in comparison to the other drug combinations. Conclusion: The use of nanoparticles functionalized with cytotoxic drugs such as cisplatin or gemcitabine alone or in combination enhances their antitumor effect and decreases the multidrug resistance in NSCLC cell line. | ||||
Keywords | ||||
Cisplatin; Gemcitabine; Multidrug resistance; Nanoparticles; Non-small cell lung cancer | ||||
Statistics Article View: 458 PDF Download: 451 |
||||